ReviewMini reviews in medicinal chemistry2026
The Multifaceted Potential of
Review in Mini reviews in medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adhatoda vasica Nees (A. vasica), known as the Malabar nut, belongs to the Acanthaceae family and is widely distributed across South and Southeast Asia. It is used in Ayurveda and Unani medicine as a therapy for human diseases, such as respiratory ailments like asthma, bronchitis, and tuberculosis. These plants are reported to be rich in alkaloids, flavonoids, tannins, and saponins, with vasicine and vasicinone as the primary bioactive compounds for their therapeutic activity. A. vasica has also been identified to contain several secondary metabolites, such as quercetin, kaempferol, and apigenin, that exhibit antioxidant, antimicrobial, anti-inflammatory, and immunomodulatory activities. The transcriptome analysis of A. vasica identified 171,064 transcripts corresponding to 55,528 genes, which are associated with key biosynthetic pathways. Therefore, these A. vasica were overharvested, precisely because of their widespread medicinal use and habitat destruction, and have been placed in the threatened species category in India. This review will emphasize the need for sustainable cultivation practices and biotechnological applications in order to preserve its availability for its therapeutic benefits. Moreover, clinical trials are necessary to validate its effectiveness and safety for its therapeutic applications. Integrating traditional knowledge with modern biotechnological advancements, the A. vasica plant could be a potential contributor to the pharmaceutical industry, developing new drugs with little or no adverse effects that can improve the quality of life of patients during treatment.
Indexed as
Identifiers
42015366What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.